(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

US10098883B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Jorma HAßFELD · Mülheim an der Ruhr, DE
• Tom KINZEL · Mülheim an der Ruhr, DE
• Johannes Köbberling · Neuss, DE
• Yolanda Cancho-Grande · Leverkusen, DE
• Kristin Beyer · Mainz, DE
• Susanne Röhrig · Hilden, DE
• Maria Köllnberger · Velbert, DE
• Michael Sperzel · Kierspe, DE
• Nils Burkhardt · Velbert, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Christian Stegmann · Berlin, DE
• Joachim Schuhmacher · Wuppertal, DE
• Matthias Werner · Wuppertal, DE
• Manuel Ellermann · Wuppertal, DE

Key dates

• Filing date: Jan 26, 2017
• Grant date: Oct 16, 2018
• Expiry date: Jan 26, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.